Large VA Study: GLP-1 Drugs Do Not Increase Depression Risk Compared to DPP-4 Inhibitors
In a retrospective cohort of 139,608 US veterans, GLP-1 receptor agonists showed no significant increase in incident depression (RR 1.02, 95% CI 0.97-1.07) compared to DPP-4 inhibitors within 1 year of starting treatment — addressing safety concerns raised by FDA warnings.
Quick Facts
What This Study Found
Incident depression within 1 year: GLP-1 RA group 7.7% (2,263/34,130) vs DPP-4i group 6.3% (6,602/105,478). Adjusted relative risk: 1.02 (95% CI: 0.97-1.07, not significant). All sensitivity analyses also non-significant.
Key Numbers
Study period: June 2013 to June 2020. Compared GLP-1RA vs. DPP-4 inhibitor initiators in the Veterans Health Administration.
How They Did This
Retrospective cohort study using VA healthcare data (June 2013-June 2020). 34,130 GLP-1 RA initiators vs 105,478 DPP-4i initiators. Primary outcome: incident depression (new diagnosis or new antidepressant) within 1 year. Multivariable log-binomial regression adjusting for demographics, comorbidities, prior medications.
Why This Research Matters
FDA labeling warnings about suicidal thoughts and behaviors on GLP-1 weight-loss drugs have caused significant patient and clinician concern. This large real-world study provides reassuring evidence that GLP-1 drugs don't increase depression risk — critical safety data as millions of people start these medications.
The Bigger Picture
As GLP-1 drugs are prescribed to millions for diabetes and obesity, resolving safety concerns about psychiatric effects is critical. This study joins growing evidence that GLP-1 drugs may actually improve mental health through weight loss and metabolic improvements, rather than worsening it — though continued pharmacovigilance is warranted.
What This Study Doesn't Tell Us
Retrospective observational design — cannot prove causation. VA population is predominantly male and older, limiting generalizability. Depression detection relies on diagnosis codes and antidepressant prescriptions, which may miss cases. Only 1-year follow-up. Did not separate individual GLP-1 RAs or doses. DPP-4i comparator may also have mental health effects.
Questions This Raises
- ?Should the FDA suicidal ideation warning be reconsidered given accumulating negative evidence?
- ?Do specific GLP-1 RAs (semaglutide vs liraglutide vs dulaglutide) differ in psychiatric effects?
- ?Does the weight-loss indication carry different psychiatric risk than the diabetes indication?
Trust & Context
- Key Stat:
- RR 1.02 (not significant) After adjusting for all confounders, GLP-1 RA users had essentially the same depression risk as DPP-4i users — no increase detected in 139,608 patients over 7 years
- Evidence Grade:
- Rated strong: large cohort (139K patients), 7-year study period, robust statistical adjustment, and active comparator design. Limited by retrospective/observational nature.
- Study Age:
- Published in 2024. Directly addresses current FDA safety labeling concerns for GLP-1 weight loss drugs.
- Original Title:
- Glucagon-like peptide receptor agonists and risk for depression.
- Published In:
- Primary care diabetes, 18(4), 422-426 (2024)
- Database ID:
- RPEP-09359
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs like Ozempic cause depression?
This large study of nearly 140,000 patients found no increased depression risk with GLP-1 drugs compared to a similar diabetes medication. Despite FDA warnings about suicidal thoughts on weight-loss labels, the actual evidence doesn't support a meaningful psychiatric risk. However, any patient experiencing mood changes should discuss them with their doctor.
Why does the FDA label warn about suicidal thoughts if studies don't show increased risk?
FDA labeling sometimes includes precautionary warnings based on individual case reports rather than population-level data. This study is part of growing evidence that GLP-1 drugs don't actually increase psychiatric risk in large populations. The FDA may revisit these warnings as more safety data accumulates.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09359APA
Tagliapietra, Gabriella A; Cantrell, Matthew A; Lund, Brian C. (2024). Glucagon-like peptide receptor agonists and risk for depression.. Primary care diabetes, 18(4), 422-426. https://doi.org/10.1016/j.pcd.2024.05.005
MLA
Tagliapietra, Gabriella A, et al. "Glucagon-like peptide receptor agonists and risk for depression.." Primary care diabetes, 2024. https://doi.org/10.1016/j.pcd.2024.05.005
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like peptide receptor agonists and risk for depress..." RPEP-09359. Retrieved from https://rethinkpeptides.com/research/tagliapietra-2024-glucagonlike-peptide-receptor-agonists
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.